Results 111 to 120 of about 18,081 (204)

Cannabidiol in Periodontal Therapy-Is There Hope or Just a Bias? A Systematic Review. [PDF]

Biomedicines
Ștefănescu R, Tero-Vescan A, Vari CE, Sita D, Ősz BE.   +4 more
europepmc   +1 more source

In Vitro Metabolism of Δ8‐, Δ9‐, and Δ10‐THC in Human Hepatocytes: Distinct Δ10‐THC Biotransformation and Implications for Drug Testing

Drug Testing and Analysis, Volume 18, Issue 8, Page 1114-1121, August 2026.
Δ8‐THC and Δ9‐THC showed comparable metabolic profiles. In contrast, Δ10‐THC underwent extensive glucuronidation and hydroxylation, with only minor formation of a carboxy metabolite, indicating a markedly different metabolic pathway. These differences may increase the risk of misidentification and misinterpretation in cannabis drug testing.
Robert Kronstrand, Henrik Green, Markus Loh, Fabian Rüttimann, Manuela Carla Monti   +4 more
wiley   +1 more source

Adjunctive Cannabidiol for Drug-Resistant Epilepsy: A Systematic Review and Meta-Analysis of Randomized Trials Across Syndromes, Formulations, and Dose Ranges. [PDF]

Ther Clin Risk Manag
Pratama R, Muhaimin M, Khairinisa MA, Chaerunisaa AY.   +3 more
europepmc   +1 more source

Unveiling sleep disturbances in KCNB1‐related disorders: Insights from a cohort of 78 individuals

Epilepsia Open, Volume 11, Issue 4, Page 1159-1170, August 2026.
Abstract Objectives Sleep disturbances are frequent comorbidities in epilepsies and developmental encephalopathies. This study aimed to characterize sleep abnormalities in individuals with KCNB1‐related disorders, focusing on their prevalence, clinical manifestations, and impact on daily functioning.
Giovanna Scorrano, Delphine Breuillard, Anais Thimon, Nicole Chemaly, Rima Nabbout   +4 more
wiley   +1 more source

Hypersensitivity reaction risk when restarting cenobamate after discontinuation: Insights from a prolonged hospitalized cohort

Epilepsia Open, Volume 11, Issue 4, Page 1255-1262, August 2026.
Abstract Objective To evaluate the risk of hypersensitivity reactions, including dermatological rashes, when cenobamate (CNB) is restarted at maintenance doses after temporary discontinuation. Methods We leveraged the natural experiment of long antiseizure medication discontinuation during intracranial EEG evaluation and conducted a retrospective ...
Marina Feldman, Andreas Alexopoulos, Juan Bulacio, Dileep Nair, Vineet Punia   +4 more
wiley   +1 more source

Plasma and urinary exposure of cannabidiol and cannabidiolic acid in horses following consumption of contaminated feed. [PDF]

Ir Vet J
Ekstrand C, Michanek P, Hernlund E, Gehring R, Salomonsson M.   +4 more
europepmc   +1 more source

Cannabidiol reduces atypical absence seizures and epileptic spasms in a Gabrb3+/D120N mouse model of Lennox–Gastaut syndrome

Epilepsia Open, Volume 11, Issue 4, Page 1263-1275, August 2026.
Abstract Objective Lennox–Gastaut syndrome (LGS) is a drug‐resistant developmental and epileptic encephalopathy (DEE). Preclinical drug development for LGS is constrained by a lack of syndrome‐relevant animal models. We aimed to evaluate a Gabrb3+/D120N knock‐in (KI) mouse model of LGS by quantifying atypical absence seizures and epileptic spasms and ...
Thomas Harman, Laura A. Sharman, Ka Lai Yip, Miguel Bedoya‐Pérez, Vaishali Janve, Jonathon C. Arnold   +5 more
wiley   +1 more source

Short-Term Daily Oral Administration of Cannabidiol Does Not Impact Rebound Tonometry Intraocular Pressure or Schirmer Tear Test Values in Healthy Adult Horses. [PDF]

Vet Ophthalmol
Diehl K, Sheridan C, Reed R.
europepmc   +1 more source

Beyond seizures: A multidimensional approach to non‐seizure issues in Lennox–Gastaut syndrome. Insights from Italian experts

Epilepsia Open, Volume 11, Issue 4, Page 1075-1094, August 2026.
Abstract Non‐seizure issues (NSIs), including cognition, behavior/psychiatric symptoms, adaptive and social functioning, sleep, autonomic, and motor impairments, often shape day‐to‐day outcomes in Lennox–Gastaut syndrome (LGS) more than seizures, yet clinicians lack LGS‐specific, feasible assessment pathways.
Giancarlo Di Gennaro, Domenica Immacolata Battaglia, Paolo Bonanni, Gian Marco Duma, Antonietta Coppola, Edoardo Ferlazzo, Dario Pruna, Carlo Di Bonaventura   +7 more
wiley   +1 more source

Safety of cannabidiol isolate from <i>Cannabis sativa</i> L. as a novel food pursuant to Regulation (EU) 2015/2283. [PDF]

EFSA J
EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Turck D, Bohn T, Cámara M, Castenmiller J, De Henauw S, Jos Á, Maciuk A, Mangelsdorf I, McNulty B, Naska A, Pentieva K, Siani A, Thies F, Cubadda F, McArdle HJ, Trezza V, Albert O, Beneventi E, Laganaro M, Nuin Garciarena I, Rossi A, Berrío Cruz S, Seminati F, Magani M, Hirsch-Ernst KI.   +26 more
europepmc   +1 more source